Synthesis of Styryl-phenyl-ureas as Dual-targeted Inhibitors of PD-L1 and VEGFR-2

rogrammed death-ligand 1 (PD-L1, cluster of differentiation 274, CD274, B7 homolog 1 or B7-H1) is a transmembrane protein that plays a major role in suppressing the adaptive arm of immune system during particular events such as tissue allografts, pregnancy, autoimmune disease and some other pathological disease states. Upregulation of PD-L1 may allow cancers to evade the host immune system.

Vascular endothelial growth factor receptor 2 (VEGFR-2, Kinase insert domain receptor, KDR, CD309, FLK1) is a VEGF receptor that plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Abnormal functioning of VEGFR-2 is associated with cancer.

We offer the chemical optimization service - synthesis of targets-specific set of styryl-phenyl-urea derivatives as dual-targeted inhibitors of PD-L1 and VEGFR-2. These novel compounds will be selected from a set of 3,000+ virtual styryl-phenyl-ureas using our company’s proprietary molecular modeling platform, synthesized and provided for your biological projects.

This set of novel analogs will be synthesized exclusively upon your request.

This is referred to a paper from European Journal of Medicinal Chemistry* which showed that authors designed and evaluated styryl-phenyl-ureas as dual-targeted inhibitors of PD-L1 and VEGFR-2 in order to overcome resistance phenomena offered by cancer.